#16
|
||||
|
||||
Àëåêñåé Ãåííàäüåâè÷! Ïî÷åìó â ïî÷å÷íûå ïîñòàâèëè ãðàôòû, à íå ñòåíòû?
|
#17
|
|||
|
|||
Ïîñòàâèëè ñòåíò-ãðàôòû advanta 6-59.
Õîðîøèé âîïðîñ. Òàê ïðèíÿòî. Âîçìîæíî, ýòî ñâÿçàíî ñ òåì, ÷òî óìåíüøàåòñÿ âåðîÿòíîñòü 1À ýíäîëèêà, ò.ê. âåñü ïîòîê êðîâè ïî áîêàì ãðàôòà íàïðàâëÿåòñÿ òîëüêî â ïî÷å÷íûå àðòåðèè. Ó äàííîãî ïàöèåíòà ýòî íå î÷åâèäíî, ïîòîìó ÷òî ïîêðûòàÿ ÷àñòü àîðòàëüíîãî ãðàôòà çàõâàòûâàåò òîëüêî óñòüÿ ïî÷å÷íûõ àðòåðèé. ß ïèñàë óæå, ÷òî ïðîêñèìàëüíûé êðàé ïîêðûòîé ÷àñòè àîðòàëüíîãî ãðàôòà ÿ ðàñïðàâëÿë ñðàçó ïîä óñòüå ÂÁÀ, íî â ìîìåíò äèëÿòàöèè òðåõ áàëëîíîâ (áàëëîí â àîðòå è äâà â ïî÷å÷íûõ àðòåðèÿõ) ñòåíò-ãðàôò ïîïîëç âíèç. Ê ñ÷àñòüþ óñïåë çàôèêñèðîâàòüñÿ â íóæíîì ìåñòå. Ïðè÷èí ìîæåò áûòü òðè: íåïðàâèëüíî ïîäîáðàíû äèàìåòðû âñåõ óñòðîéñòâ, ïëîòíûå âûñòóïàþùèå áëÿøêè â àîðòå ìåæäó óñòüÿìè ïî÷å÷íûõ àðòåðèé è ÂÁÀ, ýòî îáû÷íàÿ ñèòóàöèÿ è íóæíî èñïîëüçîâàòü êàêèå-òî äîïîëíèòåëüíûå ìàíåâðû. Ìîæåò áûòü ó óâàæàåìûõ ïðîêòîðîâ äðóãîå ìíåíèå? ß äóìàþ, ÷òî â ýêñòðåííîé ñèòóàöèè, åñëè íåò ïî÷å÷íûõ ãðàôòîâ è íåò äðóãîé àëüòåðíàòèâû, ìîæíî ïîñòàâèòü îáû÷íûå ñòåíòû. Ïî êðàéíåé ìåðå â îäíó àðòåðèþ. Íàâåðíÿêà, ýòî áóäåò ðàáîòàòü. |
#18
|
||||
|
||||
Ïî÷åìó íàäî îäíîìîìåíòíî ðàñïðàâëÿòü òðè ãðàôòà, à íå ïî äðóãîìó, ñíà÷àëà îñíîâíîé àîðòàëüíûé, çàòåì ïî÷å÷íûå.
|
#19
|
|||
|
|||
Àîðòàëüíûé ðàñïðàâëÿþò ïåðâûì.  ñòàíäàðòíûé ïðîòîêîë ëþáîãî ýíäîïðîòåçèðîâàíèÿ âõîäèò äèëÿòàöèÿ êîìïëàéñíûì áàëëîíîì íåêîòîðûõ êðèòè÷åñêèõ òî÷åê ïðîòåçà, â òîì ÷èñëå è ïðîêñèìàëüíîãî ïîêðûòîãî êîíöà. Ëîãè÷íî, ÷òîáû íå çàäàâèòü ïî÷å÷íûå ñòåíòû è óìåíüøèòü ñëåïûå êàðìàíû ìåæäó ñòåíòàìè, äåëàòü äèëÿòàöèþ ñðàçó âñåõ ñòåíòîâ.
|
#20
|
||||
|
||||
Ëåøà, ïðîòîêîëû ïîïðîñè ó Ðîìû, ÿ â îòïóñêå.
Êñòàòè, ìû ðóòèííî ãðàôò íå äèëàòèðóåì. Òîëüêî â ñëó÷àå àêòèâíîãî 1à ýíäîëèêà. Êàê âñåãäà, ÷åì áîëüøå áàëëîíà, òåì áîëüøå äèññåêöèé.
__________________
Àáóãîâ Ñåðãåé Àëåêñàíäðîâè÷. Ðîññèéñêèé Íàó÷íûé Öåíòð Õèðóðãèè èì. àêàäåìèêà Á.Â. Ïåòðîâñêîãî. |
#21
|
|||
|
|||
|
#22
|
||||
|
||||
Ïðè ÷èìíè, äóìàþ, íàäî. Âñ¸-òàêè, áàëëîíû â ïî÷êàõ êîìïðîìåòèðóþò ãðàôò.
__________________
Àáóãîâ Ñåðãåé Àëåêñàíäðîâè÷. Ðîññèéñêèé Íàó÷íûé Öåíòð Õèðóðãèè èì. àêàäåìèêà Á.Â. Ïåòðîâñêîãî. |
|
#23
|
|||
|
|||
Öèòàòà:
Comparison of fenestrated endovascular aneurysm repair and chimney graft techniques for pararenal aortic aneurysm Journal of Vascular Surgery Volume 60, Issue 1, Pages 31–39, July 2014 "Objective This study compared early-term and midterm results of endovascular repair (EVAR) of juxtarenal or pararenal aortic aneurysms (PAAs) using fenestrated stent grafting (f-EVAR) and the chimney grafting (c-EVAR) technique. Methods Consecutive patients with PAAs who underwent f-EVAR using commercially available devices and c-EVAR in a tertiary vascular center from January 2006 to April 2013 were evaluated, including a retrospective scrutiny and update of a prospectively maintained database, calculation and comparison of perioperative mortality and morbidity, overall survival, reintervention-free rate, branch event-free rate, reconstructed vessel patency, and collection of data about intraoperative events, perioperative complications and reinterventions, and midterm sac behavior. Results During the study period, 80 patients (72 men) underwent f-EVAR and 38 (34 men) underwent c-EVAR. All f-EVAR patients were operated on electively, whereas six c-EVAR patients (15.8%; P = .002) were operated on in an emergent setting. The preoperative PAA diameter was significantly smaller in the f-EVAR group than in the c-EVAR group (58.6 ± 8.6 mm vs 65.9 ± 15.3 mm; P = .003). The mean number of reconstructed vessels per patient was 2.4 ± 0.7 (median, two) for the f-EVAR group and 1.6 ± 0.7 (median, one) for the c-EVAR group (P < .0001). The f-EVAR and c-EVAR groups did not differ in 30-day mortality (6.3% vs 7.9%; P = .71) or in moderate to severe complications (27.5% vs 39.5%; P = 1.0). Median follow-up duration was 14 months, (range, 0-88 months) in the f-EVAR group and 12 months (range, 0-48 months) in the c-EVAR group. After 2 years, estimated survival rates (77.3% vs 71.8%), reintervention-free rates (71.4% vs 72.0%), reconstructed vessel event-free rates (90.5% vs 84.1%), and primary patency of reconstructed vessel rates (97.1% vs 87.6%) were not statistically different. During follow-up, sac shrinkage (≥5 mm) was observed in 43.4% of f-EVAR patients and in 30.6% of c-EVAR patients (no statistical difference). Conclusions In this limited retrospective series, short-term and midterm results of f-EVAR and c-EVAR were not statistically different. c-EVAR could be an attractive option for patients not suitable for f-EVAR." Òàì åùå èíòåðåñíûé ñïèñîê ëèòåðàòóðû. |
#24
|
|||
|
|||
Öèòàòà:
Ïåðåä EVAR: ìû ðåêîìåíäóåì âûïîëíèòü ÌÑÊÒ ñ êîíòðàñòèðîâàíèåì îò óãëà ÷åëþñòè äî âåðõíåé/ñðåäíåé òðåòè áåäðà. Øàã 0.5-3ìì. Ïîñëå EVAR: êëàññè÷åñêèå òðåáîâàíèÿ - ÷åðåç 1, 3, 6, 12 ìåñ, äàëåå åæåãîäíî. Ôàçû: áåç êîíòðàñòà, àðòåðèàëüíàÿ, âåíîçíàÿ. Ò.ê. âûøå îïèñàííàÿ ñõåìà ïåðåêî÷åâàëà èç èññëåäîâàíèé è â ðåàëüíîé êëèí. ïðàêòèêå ÷ðåçìåðíî àãðåññèâíà, ìû ÷àùå âñåãî èñïîëüçóåì ìîäèôèöèðîâàííóþ (ìåíåå îáëó÷àþùóþ): îò T9-10 äî ñðåäíåé òðåòè áåäðà: áåç êîíòðàñòà, àðòåðèàëüíàÿ ôàçà è âåíîçíàÿ ôàçà - ÷åðåç 1 ìåñÿö. Åñëè ïîäòåêàíèé íåò, äàëåå ÷åðåç ãîä. Åñëè íà ãîäîâîé ÌÑÊÒ îòìå÷àåòñÿ ñòàáèëèçàöèÿ äèàìåòðà àíåâðèçìàòè÷åñêîãî ìåøêà èëè åãî óìåíüøåíèå, íåîáõîäèìîñòè â ðåãóëÿðíîì ïðîâåäåíèè ÌÑÊÒ, íà íàø âçãëÿä, íåò. Äàëüíåéøèé êîíòðîëü ñ ïîìîùüþ óëüòðàçâóêà.  ñëó÷àå ïîÿâëåíèé æàëîá, ïðîáëåì è ò.ï. - ÌÑÊÒ êàê ïåðåä EVAR. |
#25
|
|||
|
|||
Öèòàòà:
|